Compare ACGL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACGL | ONC |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | Bermuda | Switzerland |
| Employees | N/A | 12000 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0B | 31.4B |
| IPO Year | N/A | N/A |
| Metric | ACGL | ONC |
|---|---|---|
| Price | $96.06 | $297.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $108.79 | ★ $374.75 |
| AVG Volume (30 Days) | ★ 1.5M | 209.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $759.19 |
| Revenue Next Year | $3.72 | $14.51 |
| P/E Ratio | ★ $8.45 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $82.45 | $196.53 |
| 52 Week High | $102.90 | $385.22 |
| Indicator | ACGL | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 53.64 | 49.22 |
| Support Level | $94.84 | $295.97 |
| Resistance Level | $97.15 | $300.00 |
| Average True Range (ATR) | 1.63 | 7.30 |
| MACD | 0.25 | 2.54 |
| Stochastic Oscillator | 90.49 | 97.23 |
Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.